The cardiovascular effects of insulin

Bibliography

• World Health Organization. The top 10 causes of death. 2013. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/ [Last accessed 24 February 2014]
   Google Scholar
• DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94
   PubMed Web of Science ®Google Scholar
• Zimmet PZ. Hyperinsulinemia – how innocent a bystander? Diabetes Care 1993;16(Suppl 3):56-70
   PubMedGoogle Scholar
• Aroor AR, McKarns S, Demarco VG, et al. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism 2013;62:1543-52
   PubMed Web of Science ®Google Scholar
• Stout RW. Insulin and atheroma. 20-yr perspective. Diabetes Care 1990;13:631-54
   PubMed Web of Science ®Google Scholar
• Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979;2:131-41
   PubMedGoogle Scholar
• Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease. Paris prospective study. Diabetes Care 1991;14:461-9
   PubMed Web of Science ®Google Scholar
• Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2:154-60
   PubMedGoogle Scholar
• Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris prospective study, ten years later. Horm Metab Res Suppl 1985;15:41-6
   PubMedGoogle Scholar
• Shanik MH, Xu Y, Skrha J, et al. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 2008;31(Suppl 2):S262-8
   PubMed Web of Science ®Google Scholar
• Yu Q, Gao F, Ma XL. Insulin says NO to cardiovascular disease. Cardiovasc Res 2011;89:516-24
   PubMed Web of Science ®Google Scholar
• Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007;28:463-91
   PubMed Web of Science ®Google Scholar
• Muniyappa R, Iantorno M, Quon MJ. An integrated view of insulin resistance and endothelial dysfunction. Endocrinol Metab Clin North Am 2008;37:685-711; ix-x
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318-68
   PubMed Web of Science ®Google Scholar
• Mather KJ. The vascular endothelium in diabetes – a therapeutic target? Rev Endocr Metab Disord 2013;14:87-99
   PubMed Web of Science ®Google Scholar
• Steinberg HO, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94:1172-9
   PubMed Web of Science ®Google Scholar
• Scherrer U, Randin D, Vollenweider P, et al. Nitric oxide release accounts for insulin’s vascular effects in humans. J Clin Invest 1994;94:2511-15
   PubMed Web of Science ®Google Scholar
• Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7
   PubMed Web of Science ®Google Scholar
• Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000;101:1539-45
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by akt-dependent phosphorylation. Nature 1999;399:601-5
   PubMed Web of Science ®Google Scholar
• Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003;284:R1-12
   PubMed Web of Science ®Google Scholar
• Lincoln TM, Dey N, Sellak H. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol (1985) 2001;91:1421-30
   PubMed Web of Science ®Google Scholar
• Begum N, Ragolia L, Rienzie J, et al. Regulation of mitogen-activated protein kinase phosphatase-1 induction by insulin in vascular smooth muscle cells. evaluation of the role of the nitric oxide signaling pathway and potential defects in hypertension. J Biol Chem 1998;273:25164-70
   PubMed Web of Science ®Google Scholar
• Vincent MA, Barrett EJ, Lindner JR, et al. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab 2003;285:E123-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Vincent MA, Richards SM, et al. Insulin sensitivity of muscle capillary recruitment in vivo. Diabetes 2004;53:447-53
   PubMed Web of Science ®Google Scholar
• Vincent MA, Clerk LH, Lindner JR, et al. Mixed meal and light exercise each recruit muscle capillaries in healthy humans. Am J Physiol Endocrinol Metab 2006;290:E1191-7
   PubMed Web of Science ®Google Scholar
• Vincent MA, Clerk LH, Lindner JR, et al. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 2004;53:1418-23
   PubMed Web of Science ®Google Scholar
• Barrett EJ, Eggleston EM, Inyard AC, et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 2009;52:752-64
   PubMed Web of Science ®Google Scholar
• Barrett EJ, Wang H, Upchurch CT, Liu Z. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am J Physiol Endocrinol Metab 2011;301:E252-63
   PubMed Web of Science ®Google Scholar
• Sherwin RS, Kramer KJ, Tobin JD, et al. A model of the kinetics of insulin in man. J Clin Invest 1974;53:1481-92
   PubMed Web of Science ®Google Scholar
• Chiu JD, Richey JM, Harrison LN, et al. Direct administration of insulin into skeletal muscle reveals that the transport of insulin across the capillary endothelium limits the time course of insulin to activate glucose disposal. Diabetes 2008;57:828-35
   PubMed Web of Science ®Google Scholar
• Aird WC. Phenotypic heterogeneity of the endothelium: I. structure, function, and mechanisms. Circ Res 2007;100:158-73
   PubMed Web of Science ®Google Scholar
• Eggleston EM, Jahn LA, Barrett EJ. Hyperinsulinemia rapidly increases human muscle microvascular perfusion but fails to increase muscle insulin clearance: evidence that a saturable process mediates muscle insulin uptake. Diabetes 2007;56:2958-63
   PubMed Web of Science ®Google Scholar
• Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997;96:4104-13
   PubMed Web of Science ®Google Scholar
• Kubota T, Kubota N, Kadowaki T. The role of endothelial insulin signaling in the regulation of glucose metabolism. Rev Endocr Metab Disord 2013;14:207-16
   PubMed Web of Science ®Google Scholar
• Potenza MA, Addabbo F, Montagnani M. Vascular actions of insulin with implications for endothelial dysfunction. Am J Physiol Endocrinol Metab 2009;297:E568-77
   PubMed Web of Science ®Google Scholar
• Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 2009;20:295-302
   PubMed Web of Science ®Google Scholar
• Mukai Y, Wang CY, Rikitake Y, Liao JK. Phosphatidylinositol 3-kinase/protein kinase akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol 2007;292:H1937-42
   PubMed Web of Science ®Google Scholar
• Montagnani M, Golovchenko I, Kim I, et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 2002;277:1794-9
   PubMed Web of Science ®Google Scholar
• Luscher TF, Yang Z, Tschudi M, et al. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res 1990;66:1088-94
   PubMed Web of Science ®Google Scholar
• Kelly LK, Wedgwood S, Steinhorn RH, Black SM. Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase. Am J Physiol Lung Cell Mol Physiol 2004;286:L984-91
   PubMed Web of Science ®Google Scholar
• Mather KJ, Mirzamohammadi B, Lteif A, et al. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 2002;51:3517-23
   PubMed Web of Science ®Google Scholar
• Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004;53:2060-6
   PubMed Web of Science ®Google Scholar
• Thorin E, Clozel M. The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol 2010;60:1-26
   PubMedGoogle Scholar
• Baron AD, Brechtel G. Insulin differentially regulates systemic and skeletal muscle vascular resistance. Am J Physiol 1993;265:E61-7
   PubMed Web of Science ®Google Scholar
• Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000;105:311-20
   PubMed Web of Science ®Google Scholar
• Potenza MA, Marasciulo FL, Chieppa DM, et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 2005;289:H813-22
   PubMed Web of Science ®Google Scholar
• Piatti PM, Monti LD, Conti M, et al. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 1996;45:316-21
   PubMed Web of Science ®Google Scholar
• Nilsson D, Wackenfors A, Gustafsson L, et al. PKC and MAPK signalling pathways regulate vascular endothelin receptor expression. Eur J Pharmacol 2008;580:190-200
   PubMed Web of Science ®Google Scholar
• Li G, Barrett EJ, Wang H, et al. Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. Endocrinology 2005;146:4690-6
   PubMed Web of Science ®Google Scholar
• Sartori C, Trueb L, Nicod P, Scherrer U. Effects of sympathectomy and nitric oxide synthase inhibition on vascular actions of insulin in humans. Hypertension 1999;34:586-9
   PubMed Web of Science ®Google Scholar
• Marban S, Roth J. Transgenic hyperinsulinemia: a mouse model of insulin resistance and glucose intolerance without obesity. In: Shafrir E, editor. Lessons from animal diabetes VI. 6th edition. Birkhauser, Boston; 1996. p. 201; 202-224
   Google Scholar
• Rizza RA, Mandarino LJ, Genest J, et al. Production of insulin resistance by hyperinsulinaemia in man. Diabetologia 1985;28:70-5
   PubMed Web of Science ®Google Scholar
• Gavin JR III, Roth J, Neville DM Jr, et al. Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture. Proc Natl Acad Sci USA 1974;71:84-8
   PubMed Web of Science ®Google Scholar
• Pederson TM, Kramer DL, Rondinone CM. Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes 2001;50:24-31
   PubMed Web of Science ®Google Scholar
• Dominici FP, Burghi V, Munoz MC, Giani JF. Modulation of the action of insulin by angiotensin-(1-7). Clin Sci (Lond) 2014;126:613-30
   PubMed Web of Science ®Google Scholar
• Sheikh A. Direct cardiovascular effects of glucagon like peptide-1. Diabetol Metab Syndr 2013;5:47
   PubMedGoogle Scholar
• Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN. Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis 2013;227:216-21
   PubMed Web of Science ®Google Scholar
• Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol 2009;53:S14-20
   PubMed Web of Science ®Google Scholar
• Imrie H, Abbas A, Kearney M. Insulin resistance, lipotoxicity and endothelial dysfunction. Biochim Biophys Acta 2010;1801:320-6
   PubMed Web of Science ®Google Scholar
• Schulz E, Jansen T, Wenzel P, et al. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008;10:1115-26
   PubMed Web of Science ®Google Scholar
• Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res 2006;71:247-58
   PubMed Web of Science ®Google Scholar
• Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Anti-inflammatory effects of insulin and the pro-inflammatory effects of glucose. Semin Thorac Cardiovasc Surg 2006;18:293-301
   PubMedGoogle Scholar
• Zhou MS, Schulman IH, Zeng Q. Link between the renin-angiotensin system and insulin resistance: implications for cardiovascular disease. Vasc Med 2012;17:330-41
   PubMed Web of Science ®Google Scholar
• Andreozzi F, Laratta E, Sciacqua A, et al. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ Res 2004;94:1211-18
   PubMed Web of Science ®Google Scholar
• Park K, Li Q, Rask-Madsen C, et al. Serine phosphorylation sites on IRS2 activated by angiotensin II and protein kinase C to induce selective insulin resistance in endothelial cells. Mol Cell Biol 2013;33:3227-41
   PubMed Web of Science ®Google Scholar
• Pan P, Fu H, Zhang L, et al. Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells. BMC Cell Biol 2010;11:36
   PubMedGoogle Scholar
• Madonna R, De Caterina R. Cellular and molecular mechanisms of vascular injury in diabetes – part II: cellular mechanisms and therapeutic targets. Vascul Pharmacol 2011;54:75-9
   PubMed Web of Science ®Google Scholar
• Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin 2012;8:609-17
   PubMed Web of Science ®Google Scholar
• Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. mortality results. Diabetes 1970;19(Suppl 2):789-830
   PubMedGoogle Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
   PubMed Web of Science ®Google Scholar
• Ceriello A. Hypothesis: the “metabolic memory”, the new challenge of diabetes. Diabetes Res Clin Pract 2009;86(Suppl 1):S2-6
   PubMedGoogle Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85
   PubMed Web of Science ®Google Scholar
• Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000;106:453-8
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group, Patel A. MacMahon S, Chalmers J, Neal B, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• BARI 2D Study Group. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-15
   PubMed Web of Science ®Google Scholar
• Mellbin LG, Malmberg K, Norhammar A, et al. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the diabetes mellitus insulin-glucose infusion in acute myocardial infarction (DIGAMI) 2 study. Diabetologia 2011;54:1308-17
   PubMed Web of Science ®Google Scholar
• Gamble JM, Simpson SH, Eurich DT, et al. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 2010;12:47-53
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-28
   PubMed Web of Science ®Google Scholar
• Control Group. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-98
   PubMed Web of Science ®Google Scholar
• Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-18
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
   PubMed Web of Science ®Google Scholar